Adlai Nortye Ltd. (ANL)
D
Pipeline Grade
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | PHASE1 | Active Not Recruiting | 63 |
| NCT07252479 | Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | PHASE1 | Recruiting | 91 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.